var data={"title":"Sargramostim: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Sargramostim: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6936?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=sargramostim-drug-information\" class=\"drug drug_general\">see &quot;Sargramostim: Drug information&quot;</a> and <a href=\"topic.htm?path=sargramostim-patient-drug-information\" class=\"drug drug_patient\">see &quot;Sargramostim: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F220032\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Leukine</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F220033\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Leukine</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1049810\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Colony-Stimulating Factor</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Hematopoietic Agent</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11445029\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Neutropenia:</b> Limited data available; efficacy result variable: SubQ: 10 mcg/kg/dose once daily for 5 days. The PROGRAMS trial (single-blind, multicenter) evaluated use in 280 premature neonates (GA: &le;31 weeks; weight: &le;10th percentile body weight) and showed a correction of neutropenia but no reduction in sepsis or improved survival (Carr, 2009); an extension study also reported no difference in developmental, neurological, or general health outcomes in former premature neonates who received sargramostim compared to placebo (Marlow, 2013)  </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1049802\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=sargramostim-drug-information\" class=\"drug drug_general\">see &quot;Sargramostim: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infants, Children, and Adolescents: <b> Neutrophil recovery following bone marrow transplant:</b> Limited data available:  IV: 250 mcg/m<sup>2</sup>/day (infused over 2-4 hours or SubQ) once daily for 21 days to begin 2-4 hours after the marrow infusion on day 0 of BMT or not less than 24 hours after chemotherapy (Trigg, 2000; Nemunaitis, 1991) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adults: <b>Note:</b> May round the dose to the nearest vial size (Ozer, 2000).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Acute myeloid leukemia (AML), neutrophil recovery following chemotherapy:</b> Adults &ge;55 years: IV: 250 mcg/m<sup>2</sup>/day (infused over 4 hours) starting approximately on day 11 or 4 days following the completion of induction chemotherapy (if day 10 bone marrow is hypoplastic with &lt;5% blasts), continue until ANC &gt;1500/mm<sup>3</sup> for 3 consecutive days or a maximum of 42 days.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">If a second cycle of chemotherapy is necessary, administer ~4 days after the completion of chemotherapy if the bone marrow is hypoplastic with &lt;5% blasts.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Discontinue sargramostim immediately if leukemic regrowth occurs. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Bone marrow transplant (BMT), failure or engraftment delay:</b> IV: 250 mcg/m<sup>2</sup>/day (infused over 2 hours) for 14 days; if engraftment has not occurred after 7 days off sargramostim, may repeat. If engraftment still has not occurred after 7 days off sargramostim, a third course of 500 mcg/m<sup>2</sup>/day for 14 days may be attempted. If there is still no improvement, it is unlikely that further dose escalation will be of benefit. If blast cells appear or disease progression occurs, discontinue treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Myeloid reconstitution after allogeneic or autologous bone marrow transplant:</b> IV: 250 mcg/m<sup>2</sup>/day (infused over 2 hours), begin 2-4 hours after the marrow infusion and &ge;24 hours after chemotherapy or radiotherapy, when the post marrow infusion ANC is &lt;500/mm<sup>3</sup>, and continue until ANC &gt;1500/mm<sup>3</sup> for 3 consecutive days. If blast cells appear or progression of the underlying disease occurs, discontinue treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Peripheral stem cell transplant, mobilization of peripheral blood progenitor cells (PBPC):</b> IV, SubQ: 250 mcg/m<sup>2</sup>/day IV (infused over 24 hours) or SubQ once daily; continue the same dose throughout PBPC collection. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b> Postperipheral blood progenitor cell transplantation:</b> IV, SubQ: 250 mcg/m<sup>2</sup>/day IV (infused over 24 hours) or SubQ once daily beginning immediately following infusion of progenitor cells; continue until ANC is &gt;1500/mm<sup>3</sup> for 3 consecutive days.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment for adverse effects (hematologic) or &ldquo;first dose&rdquo; effect:</b> Infants, Children, Adolescents, and Adults: If WBC &gt; 50,000/mm<sup>3</sup>, ANC is &gt;20,000/mm<sup>3</sup>, or platelets &gt;500,000/mm<sup>3</sup>, or severe adverse reaction occurs: Decrease dose by 50% or discontinue drug (based on protocol or patient's clinical condition). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F220011\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Leukine: 250 mcg (1 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F219996\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1049815\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Parenteral: </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">IV: Administer as 2-hour,  4-hour, or 24-hour infusion (indication specific). An in-line membrane filter should <b>not</b> be used for intravenous administration. Do not shake solution to avoid foaming. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">SubQ: Administer reconstituted solution without further dilution; rotate injection sites; avoiding navel/waistline  </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F220028\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;display:inline\">Store intact vials at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F); do not freeze. Do not shake. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution for injection: May be stored for up to 20 days at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F) once the vial has been entered. Discard remaining solution after 20 days.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">Powder for injection: Preparations made with SWFI should be administered as soon as possible, and discarded within 6 hours of reconstitution. Solutions reconstituted with bacteriostatic water may be stored for up to 20 days at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F); do not freeze. When combining previously reconstituted solutions with freshly reconstituted solutions, administer within 6 hours following preparation; the contents of vials reconstituted with different diluents should not be mixed together.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1049814\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Accelerates myeloid recovery in patients undergoing autologous or allogeneic BMT, mobilizes hematopoietic progenitor cells into peripheral blood for collection by leukapheresis, and accelerates myeloid recovery following autologous peripheral stem cell transplantation and prolong survival in patients with graft failure or engraftment delay after BMT (FDA approved in adults); shortens time to neutrophil recovery and  reduces the incidence of severe and life-threatening infections and infections resulting in death following induction chemotherapy in older adults with acute myelogenous leukemia (AML) (FDA approved in adults &ge;55 years of age). Has also been used to increase neutrophil counts in patients with malignancies receiving myelosuppressive chemotherapy (beginning &gt;24 hour after chemotherapy) and for management of neonatal neutropenia. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F220065\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Leukine may be confused with Leukeran, leucovorin</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F220061\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Chest pain, edema, hypertension, pericardial effusion, peripheral edema, tachycardia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Anxiety, chills, headache, insomnia, malaise</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Pruritus, skin rash</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Hypercholesterolemia, hyperglycemia, hypomagnesemia, weight loss</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal pain, anorexia, diarrhea, dysphagia, gastrointestinal hemorrhage, hematemesis, nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Urinary tract infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Hyperbilirubinemia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Immunologic: Antibody development</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Arthralgia, myalgia, ostealgia, weakness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Retinal hemorrhage</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Renal: Increased blood urea nitrogen, increased serum creatinine</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Dyspnea, epistaxis, pharyngitis, pleural effusion</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Anaphylaxis, capillary leak syndrome, cardiac arrhythmia, dizziness, eosinophilia, flushing, hypotension, hypoxia, injection site reaction, leukocytosis, liver function impairment (transient), pain, prolonged prothrombin time, respiratory distress, supraventricular cardiac arrhythmia, syncope, thrombocythemia, thrombosis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F220018\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to sargramostim, yeast-derived products, or any component of the formulation; concomitant use with cytotoxic chemotherapy and radiation therapy or within 24 hours preceding/following chemotherapy or radiation therapy; patients with excessive (&ge;10%) leukemic myeloid blasts in bone marrow or peripheral blood</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F220000\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; First-dose effect: A &ldquo;first-dose effect&rdquo;, characterized by respiratory distress, hypoxia, flushing, hypotension, syncope, and/or tachycardia, may occur (rarely) with the first dose of a cycle and resolve with appropriate symptomatic treatment; symptoms do not usually occur with subsequent doses within that cycle.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Fluid retention: Edema, capillary leak syndrome, pleural and/or pericardial effusion have been reported; fluid retention has been shown to be reversible with dosage reduction or discontinuation of sargramostim with or without concomitant use of diuretics. Use with caution in patients with preexisting fluid retention, pulmonary infiltrates, or congestive heart failure; may exacerbate fluid retention.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hematologic effects: If there is a rapid increase in blood counts (ANC &gt;20,000/mm<sup>3</sup> or platelets &gt;500,000/mm<sup>3</sup>), decrease the dose by 50% or discontinue therapy. Excessive blood counts should fall to normal within 3 to 7 days after the discontinuation of therapy. Monitor CBC with differential twice weekly during treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: Serious allergic and anaphylactic reactions have been reported; discontinue immediately and initiate appropriate therapy if a serious allergic or anaphylactic reaction occurs.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Immunogenicity: Treatment with sargramostim may induce neutralizing anti-drug antibodies. Antibody formation may be related to duration of sargramostim exposure; use sargramostim for the shortest duration necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pulmonary symptoms: Sequestration of granulocytes in pulmonary circulation and dyspnea have been reported; monitor respiratory symptoms during and following IV infusion. Decrease infusion rate by 50% if dyspnea occurs; discontinue the infusion if dyspnea persists despite reduction in the rate of administration. Subsequent doses may be administered at the standard rate with careful monitoring. Use with caution in patients with hypoxia or pre-existing pulmonary disease.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiac disease: Use with caution in patients with pre-existing cardiac disease. Reversible transient supraventricular arrhythmias have been reported, especially in patients with a history of arrhythmias.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment; hyperbilirubinemia and elevated transaminases have been observed in this patient population. Monitor hepatic function at least every other week in patients with history of hepatic dysfunction.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment; serum creatinine elevations have been observed in this patient population. Monitor renal function at least every other week in patients with history of renal dysfunction.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cytotoxic chemotherapy/radiotherapy: Simultaneous administration, or administration 24 hours preceding/following cytotoxic chemotherapy or radiotherapy is contraindicated due to the sensitivity of rapidly dividing hematopoietic progenitor cells.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly patients: The American Society of Clinical Oncology (ASCO) Recommendations for the Use of WBC Growth Factors Clinical Practice Guideline Update recommend that prophylactic colony-stimulating factors be used in patients &ge;65 years with diffuse aggressive lymphoma treated with curative chemotherapy (eg, rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone), especially if patients have comorbid conditions (Smith 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric patients: Colony-stimulating factor (CSF) use in pediatric patients is typically directed by clinical pediatric protocols. The American Society of Clinical Oncology (ASCO) Recommendations for the Use of WBC Growth Factors Clinical Practice Guideline Update states that CSFs may be reasonable as primary prophylaxis in pediatric patients when chemotherapy regimens with a high likelihood of febrile neutropenia are employed. Likewise, secondary CSF prophylaxis should be limited to high-risk patients. In pediatric cancers in which dose-intense chemotherapy (with a survival benefit) is used, CSFs should be given to facilitate chemotherapy administration. CSFs should not be used in the pediatric population for non-relapsed acute lymphoblastic or myeloid leukemia when no infection is present (Smith 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Benzyl alcohol and derivatives: Some dosage forms may contain benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP [&quot;Inactive&quot; 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: CSFs should not be routinely used in the treatment of established neutropenic fever. Colony-stimulating factors may be considered in cancer patients with febrile neutropenia who are at high risk for infection-associated complications or who have prognostic factors indicative of a poor clinical outcome (eg, prolonged and severe neutropenia, age &gt;65 years, hypotension, pneumonia, sepsis syndrome, presence of invasive fungal infection, uncontrolled primary disease, hospitalization at the time of fever development) (Freifeld 2011, Smith 2006). CSFs should not be routinely used for patients with neutropenia who are afebrile. Dose-dense regimens that require CSFs should only be used within the context of a clinical trial or if supported by convincing evidence (Smith 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Efficacy: Limited response to sargramostim may be seen in patients who have received bone marrow purged by chemical agents which do not preserve an adequate number of responsive hematopoietic progenitors (eg, &lt;1.2 x 10<sup>4</sup>/kg progenitors). In patients receiving autologous bone marrow transplant, response to sargramostim may be limited if extensive radiotherapy to the abdomen or chest or multiple myelotoxic agents were administered prior to transplant.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Peripheral blood progenitor cell mobilization: Limited in vitro data suggest that when using sargramostim to mobilize peripheral blood progenitor cells, tumor cells may be released and reinfused into patients in the leukapheresis product; the effect of tumor cell reinfusion has not been well studied.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Tumor growth factor: May potentially act as a growth factor for any tumor type, particularly myeloid malignancies; caution should be exercised when using in any malignancy with myeloid characteristics. Discontinue use if disease progression occurs during treatment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13300028\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6222861\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12781&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Bleomycin: Sargramostim may enhance the adverse/toxic effect of Bleomycin. Specifically, the risk for pulmonary toxicity may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corticosteroids (Systemic): May enhance the therapeutic effect of Sargramostim. Specifically, corticosteroids may enhance the myeloproliferative effects of sargramostim.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cyclophosphamide: May enhance the adverse/toxic effect of Sargramostim. Specifically, the risk of pulmonary toxicity may be enhanced.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lithium: Sargramostim may enhance the adverse/toxic effect of Lithium. Specifically, the myeloproliferative effects may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tisagenlecleucel: Sargramostim may enhance the adverse/toxic effect of Tisagenlecleucel. <i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F220007\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F220021\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1049809\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">CBC with differential (at least twice weekly during therapy), platelets; renal/liver function tests (at least every 2 weeks); vital signs, weight; hydration status; pulmonary function</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F219999\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Sargramostim stimulates proliferation, differentiation, and functional activity of neutrophils, eosinophils, monocytes, and macrophages.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F220017\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: Increase in WBC in 7 to 14 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration: WBCs return to baseline within 1 to 2 weeks of discontinuing drug</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children 6 months to 15 years: IV: Median: 1.6 hours; range: 0.9 to 2.5 hours; SubQ: Median: 2.3 hours (0.3 to 3.8 hours) (Stute 1995)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adults: IV: ~60 minutes; SubQ: ~2.7 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: SubQ: 1 to 3 hours</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323819\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Leukine Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mcg (1): $297.01</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038802\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Interberin (AT)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sargramostim-pediatric-drug-information/abstract-text/11487763 /pubmed\" target=\"_blank\" id=\"11487763 \">11487763 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics Committee on Drugs. &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sargramostim-pediatric-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Carr R, Brocklehurst P, Dor&eacute; CJ, et al, &quot;Granulocyte-Macrophage Colony Stimulating Factor Administered as Prophylaxis for Reduction of Sepsis in Extremely Preterm, Small for Gestational Age Neonates (the PROGRAMS Trial): A Single-Blind, Multicentre, Randomised Controlled Trial,&quot; <i>Lancet</i>, 2009, 373(9659):226-33.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sargramostim-pediatric-drug-information/abstract-text/19150703/pubmed\" target=\"_blank\" id=\"19150703\">19150703</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Carr R, Modi N, Dore CJ, et al, &ldquo;A Randomized, Controlled Trial of Prophylactic Granulocyte-Macrophage Colony-Stimulating Factor in Human Newborns Less Than 32 Weeks Gestation,&rdquo; <i>Pediatrics</i>, 1999, 103(4 Pt 1):796-802. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sargramostim-pediatric-drug-information/abstract-text/10103305/pubmed\" target=\"_blank\" id=\"10103305\">10103305</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol - United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. Available at <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sargramostim-pediatric-drug-information/abstract-text/6810084 /pubmed\" target=\"_blank\" id=\"6810084 \">6810084 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lieschke GJ and Burgess AW, &ldquo;Granulocyte Colony-Stimulating Factor and Granulocyte-Macrophage Colony-Stimulating Factor,&rdquo; (1) <i>N Engl J Med</i>, 1992, 327(1):28-35. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sargramostim-pediatric-drug-information/abstract-text/1375975/pubmed\" target=\"_blank\" id=\"1375975\">1375975</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lieschke GJ and Burgess AW, &ldquo;Granulocyte Colony-Stimulating Factor and Granulocyte-Macrophage Colony-Stimulating Factor,&rdquo; (2) <i>N Engl J Med</i>, 1992, 327(2):99-106. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sargramostim-pediatric-drug-information/abstract-text/1376442/pubmed\" target=\"_blank\" id=\"1376442\">1376442</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Marlow N, Morris T, Brocklehurst P, et al. A randomised trial of granulocyte-macrophage colong-stimulating factor for neonatal sepsis: outcomes at 2 years. <i>Arch Dis Child Fetal Neonatal Ed</i>. 2013;98:46-53.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sargramostim-pediatric-drug-information/abstract-text/22542709/pubmed\" target=\"_blank\" id=\"22542709\">22542709</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nemunaitis  J, Rabinowe SN, Singer JW, et.al. Recombinant granulocyte-macrophage coloney-stimulating factor after autologous bone marrow transplantation for lymphoid cancer. <i>NEJM</i>. 1991;324:1773-1778.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sargramostim-pediatric-drug-information/abstract-text/1903847/pubmed\" target=\"_blank\" id=\"1903847\">1903847</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ozer  H, Armitage JO, Bennett CL, et al. 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. <i>J Clin Oncol</i>. 2000;18(20):3558-3585.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sargramostim-pediatric-drug-information/abstract-text/11032599/pubmed\" target=\"_blank\" id=\"11032599\">11032599</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stute N, Furman WL, Schell M, et al, &ldquo;Pharmacokinetics of Recombinant Human Granulocyte - Macrophage Colony - Stimulating Factor in Children After Intravenous and Subcutaneous Administration,&rdquo; <i>J Pharm Sci</i>, 1995, 84(7):824-8. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sargramostim-pediatric-drug-information/abstract-text/7562431/pubmed\" target=\"_blank\" id=\"7562431\">7562431</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Trigg ME, Peters C, Zimmerman MB. Administration of recombinant human granulocyte-macrophage colony-stimulating factor to children undergoing allogeneic marrow transplantation; a prospective, randomized, double-masked, placebo-controlled trial. <i>Pediatr Transplantation</i>. 2000; 4:123-131.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sargramostim-pediatric-drug-information/abstract-text/11272605/pubmed\" target=\"_blank\" id=\"11272605\">11272605</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Trissel LA, Bready BB, Kwan JW, et al, &ldquo;Visual Compatibility of Sargramostim With Selected Antineoplastic Agents, Anti-infectives, or Other Drugs During Simulated Y-Site Injection,&rdquo; <i>Am J Hosp Pharm</i>, 1992, 49(2):402-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sargramostim-pediatric-drug-information/abstract-text/1554007/pubmed\" target=\"_blank\" id=\"1554007\">1554007</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12781 Version 86.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F220032\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F220033\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1049810\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F11445029\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1049802\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F220011\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F219996\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1049815\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F220028\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1049814\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F220065\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F220061\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F220018\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F220000\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13300028\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F6222861\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F220007\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F220021\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1049809\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F219999\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F220017\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323819\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038802\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12781|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=sargramostim-drug-information\" class=\"drug drug_general\">Sargramostim: Drug information</a></li><li><a href=\"topic.htm?path=sargramostim-patient-drug-information\" class=\"drug drug_patient\">Sargramostim: Patient drug information</a></li></ul></div></div>","javascript":null}